TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus
Highlights: LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Cyprus, subject to a definitive agreement. Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity. Transfer pricing and the first-year minimum combined unit commitment will be nego
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-29 3:05 AM EDT | TempraMed Technologies Ltd.
TempraMed Announces Upsize to Offering
Toronto, Ontario--(Newsfile Corp. - September 28, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce an upsize (the "Upsized Offering") to the non-brokered private placement (the "Offering") previously announced on Wednesday, September 23, 2026. The Upsized Offering wil
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-28 5:49 PM EDT | TempraMed Technologies Ltd.
PreveCeutical Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - September 28, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 20,000,000 units (each, a "Unit") in the capital of the Company at a price of $0.03 per Unit for gross proceeds of up to $600,000. Each Unit consists of one (1) common share of the Company (each, a "Shar
Biotechnologies, Pharmaceutique, Santé
2026-09-28 5:00 PM EDT | PreveCeutical Medical Inc.
Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities
Montreal, Quebec--(Newsfile Corp. - September 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® platform, is pleased to provide a corporate update as the Company continues to execute on the strategic priorities outlined in its recent letter to shareholders. Since assuming the role
Biotechnologies, Pharmaceutique, Santé
2026-09-28 5:00 PM EDT | Defence Therapeutics Inc.
Izotropic Announces Non-Brokered Private Placement
British Columbia and Casablanca, Morocco--(Newsfile Corp. - September 25, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces the intention to complete a non-brokered private placement (the "Offering") with of 750,000 units of the Company with a st
2026-09-25 8:00 AM EDT | Izotropic Corporation
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Ontario and Chicago, Illinois--(Newsfile Corp. - September 24, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 10, 2026 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors and in favor of resolutions amending the c
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-24 5:30 PM EDT | Medexus Pharmaceuticals Inc.
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
New York and Rockville, Maryland--(Newsfile Corp. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announce that the World Health Organization has approved the proprietary name 'Herlystic'™ was approved by the World Health Organization (WHO) as the brand name for OST-HER2. The nonproprietary name daznelimgene lisbac for the ingredients
2026-09-24 8:22 AM EDT | OS Therapies
TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement
Highlights TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin American markets. The amended framework adds VIVI Med™ to the covered product portfolio, alongside VIVI Cap™ and VIVI Epi™. TempraMed received an additional commercial order from TEM, expected to be fulfilled by the end of September 2026. Initial extended-territ
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-24 2:55 AM EDT | TempraMed Technologies Ltd.
Hemostemix Non Brokered Private Placement
Calgary, Alberta--(Newsfile Corp. - September 23, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is filing a Form 4B to obtain price protection for the closing of the third tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026, to raise $1,000,000. Each Unit consists of one common share in the capital of the Company (a "Common Share") and
Biotechnologies, Pharmaceutique, Santé
2026-09-23 4:10 PM EDT | Hemostemix Inc.
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer, today announced that it will present at the Life Sciences Future 2026 Conference, taking place September 30 to October 1, 2026, at the Sheraton Valley Forge Hotel in King of Prussia, Pennsylvania. Robert Bitter
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-23 7:00 AM EDT | Phio Pharmaceuticals Corp.
TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana
Toronto, Ontario--(Newsfile Corp. - September 23, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce it has entered into a distribution agreement dated August 25, 2026 (the "Distribution Agreement") with CenterWell Pharmacy, Inc. ("CenterWell") the pharmacy services brand of Humana Inc, a m
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-23 3:05 AM EDT | TempraMed Technologies Ltd.
DIMERx Secures Second NIH Award to Advance DMX-201 for Sickle Cell Disease
San Francisco, California--(Newsfile Corp. - September 22, 2026) - DIMERx, Inc., a clinical-stage biopharmaceutical company developing novel dimer-based therapeutics, today announced that it has received a Small Business Innovation Research (SBIR) award from the National Heart, Lung, and Blood Institute (NHLBI) to advance DMX-201 for sickle cell disease (SCD). DMX-201 has the potential to become a first-line therapy for acute chest syndrome (ACS), helping reduce acute respiratory distress, sh
Biotechnologies, Pharmaceutique, Santé
2026-09-22 9:00 AM EDT | DIMERx INC.
Envoy Medical Announces New Patents, Further Expanding Global Patent Portfolio
White Bear Lake, Minnesota--(Newsfile Corp. - September 22, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the grant of two additional international patents, expanding its global intellectual property portfolio to 97 patents, consisting of 40 U.S. and 57 foreign patents. In addition, the Company has 26 pending foreign applications and 9 pending U.S. applications.
Biotechnologies, Soins de santé et hôpitaux
2026-09-22 8:30 AM EDT | Envoy Medical, Inc.
BioMark Announces Participation in upcoming MSACL 2026 and BIOHorizon 2026 Life Sciences Conferences
Vancouver, British Columbia--(Newsfile Corp. - September 21, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies focused on the early detection of lung cancer through metabolomics, is pleased to announce today its participation in two upcoming life sciences events in Quebec during the week of October 4, 2026. The Company will participate in the 16th Annual Mass Spectrometry & Advances i
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-09-21 8:30 AM EDT | BioMark Diagnostics, Inc.
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
Recent U.K. MHRA Scientific Advice Meeting (SAM) that resulted in full alignment to initiate confirmatory Phase 3 trial in U.K. with existing Phase 2 drug product paved the way Conditional Marketing Authorisation Application (CMAA) submission in the coming weeks and Phase 3 trial initiation in mid Q4/'26 following Phase 2b drug product requalification MHRA's SAM participants' recommendation to Project Orbis U.K. leadership to take the glob
2026-09-21 6:30 AM EDT | OS Therapies
TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue
Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide an interim sales update regarding its recent commercial performance. The Company reports that July 2026 sales reached approximately US$522,000, representing the highest monthly sales level in T
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-18 4:45 PM EDT | TempraMed Technologies Ltd.
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that the shareholders' eq
Biotechnologies, Pharmaceutique
2026-09-18 4:45 PM EDT | InMed Pharmaceuticals
Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements
Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-09-18 7:00 AM EDT | Theralase Technologies Inc.
Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million
Calgary, Alberta--(Newsfile Corp. - September 17, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announced today that, further to its July 16, 2026, August 19, 2026 and September 9, 2026 press releases, it intends to complete a non‐brokered private placement offering (the "Offering") of units of the Company ("Units") at a price of $0.15 per Unit. The Offering will be for a minimum of 10,000,000 Units for gross procee
2026-09-17 5:05 PM EDT | Marvel Biosciences Corp.
Marvel Biosciences fait le point sur un placement privé pouvant atteindre 3 millions de dollars
Calgary, Alberta--(Newsfile Corp. - 17 septembre 2026) - Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) (« Marvel » ou la « Société ») a annoncé aujourd'hui que, à la suite de ses communiqués de presse des 16 juillet 2026, 19 août 2026 et 9 septembre 2026, elle entend réaliser un placement privé sans courtier (le « Placement ») d'unités de la Société (les « Unités »)
2026-09-17 5:05 PM EDT | Marvel Biosciences Corp.